Phase 1 SQZ-AAC-HPV-101 Clinical Trial Observed a Confirmed Complete Response in the First Patient and a Best Overall Response of Stable Disease in Two Additional Patients in the Lowest-Dose Cohort; Anticipate Interim Data in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Monotherapy Enrollment Complete; Antici.
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Restoration Was Observed in Two Additional Patients in a Phase 1/2a Clinical Study of OpRegen An Earlier and First-Known Clinical Report of Restoration Has Been Maintained for 3 YearsRestoration Has Been Observed in Three of Four Patients Who Received OpRegen RPE Cells Across a Wide Area of Atrophy CARLSBAD, Calif.-.